Exploiting circulating lymphocytes and cell-free DNA as a source to develop minimally-invasive personalized T-cell therapies
Year: 2023
Type: dissertation
Abstract: [eng] Adoptive cell transfer (ACT) of tumor-infiltrating lymphocytes (TILs) can medi- ate tumor regression in patients with metastatic melanoma. Retrospective studies of TIL products from responders and non-responders have shown that successful TIL-ACT is associated with an expansion of T cells targeting neoantigens, which are derived from tumor-specific non-synonymous somatic mutations (NSMs) and present exquisite tumor specificity. In addition, ACT with TIL products enriched for neoantigen recognition has demonstrated antitumor activity in selected patients with epithelial tumors other than melanoma, which has fueled the interest in personalized T-cell therapies targeting neo- antigens. The identification and isolation of neoantigen-specific TILs has been possible due to advances in next-generation sequencing that enabled the rapid assessment of the tumor mutational landscape and the development of high-throughput personalized im- munological screenings. However, the need of a tumor biopsy to both identify candidate neoantigens and reactive T cells limits the broad applicability of personalized T-cell ther- apies targeting neoantigens and can underestimate tumor heterogeneity in the advanced metastatic setting. Previous reports have shown that neoantigen-specific T cells can be enriched from peripheral blood by selecting programmed death receptor-1 (PD-1)-ex- pressing lymphocytes in circulation. However, the frequency of neoantigen-specific T cells identified based on PD-1 expression remains very low and a tumor biopsy is still re- quired to identify candidate NSMs. In this thesis, we explored the use of peripheral blood as an alternative minimal- ly-invasive source to identify tumor NSMs and isolate neoantigen-specific or tumor-reac- tive T lymphocytes in patients with metastatic breast, gynecological, colorectal and head and neck cancer or chordoma. We performed whole-exome sequencing (WES) of cell-free DNA (cfDNA) to identify tumor NSMs and compared these to those identified in DNA ex- tracted from tumor biopsies (TuBx DNA). In parallel, we evaluated whether the selection of peripheral blood lymphocytes (PBLs) expressing a combination of cell-surface recep- tors, rather than the expression of PD-1 alone, could further enhance the frequency of neo- antigen-specific T cells and T-cell receptors (TCR) detected or the number of neoantigens recognized. Toidentifycirculating tumor antigen-specific T cells, wesorted CD8+ and CD4+ PBLs of ten patients with different types of epithelial cancers based on the expression of PD-1 into PD-1hi, PD-1dim and PD-1-, and in combination with the cell-surface receptors CD27, CD38, CD39, HLA-DR and 4-1BB, obtaining up to 35 CD8+ and 35 CD4+ T-cell populations for some of the patients studied. In parallel, we also expanded TILs from tumor biopsies and compared the reactivities detected in the two T-cell sources. Ex vivo expanded PBL subsets and TILs were screened using a personalized high-throughput screening strategy, which enabled the detection of T cells targeting neoantigens identified by WES from TuBx DNA and cfDNA as well as T cells recognizing cancer germline antigens. Using this approach, we detected tumor antigen-specific T cells in eight out of 10 patients analyzed. Both CD8+ and CD4+ tumor antigen-reactive T cells were preferentially enriched in T-cell subsets expressing high levels of PD-1, either alone or in combination with other cell- surface markers, being PD-1hiCD39+ the combination of markers that more consistently identified CD4+ and CD8+ tumor reactivities. More importantly, the frequency of tumor antigen-specific T lymphocytes contained in the CD8+ PD-1hiCD39+ population was consistently higher than in any other CD8+ population sorted. This was not observed in CD4+ PBLs since the frequency of neoantigen-specific T cells was highly variable among PBL populations and none of them consistently displayed higher frequencies of neoantigen-reactive lymphocytes. The selection and expansion of CD8+ PD-1hiCD39+ PBLs outperformed the classical non-specific TIL expansion in high-dose interleukin-2 (IL-2) at identifying anti-tumor CD8+ T-cell responses. In contrast, despite the total number of CD4+ reactivities detected considering all populations screened from blood was higher than in TILs, the CD4+ PD-1hiCD39+ T-cell subpopulation identified fewer reactivities than unselected TILs. When comparing tumor and cfDNA, the overlap between NSMs identified in tumor and cfDNA varied notably between patients, with two out of six patients displaying no overlap between TuBx DNA and cfDNA WES. Moreover, WES of cfDNA from six patients preferentially identified clonal somatic mutations in tumor biopsies and enabled the identification of eight of 13 neoantigens in patients displaying some degree of overlap between tumor and cell-free NSMs. Our results underscore peripheral blood as an alternative source to identify cancer-specific neoantigens and CD8+ and CD4+ neoantigen- specific T lymphocytes and TCRs, with important implications for exploiting personalized T-cell responses in advanced cancer patients.
Author: Garcia Garijo, Andrea
Institution: Universitat de Barcelona
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7037900633
